Biomimetic Codelivery Boosts Chemo for Breast Cancer

Compuscript Ltd

https://doi.org/10.1016/j.apsb.2025.04.006

This new article publication from Acta Pharmaceutica Sinica B, discusses targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery.

Triple-negative breast cancer (TNBC) is aggressive, with high recurrence rates and poor prognosis. Paclitaxel (PTX) remains a key chemotherapeutic agent for TNBC, but its efficacy diminishes due to the emergence of drug resistance, largely driven by cancer stem-like cells (CSCs), vasculogenic mimicry (VM) formation and tumor immunosuppressive microenvironment (TIME). Pyruvate kinase M2 (PKM2) is highly expressed in TNBC, and is a potential target for TNBC treatment.

The authors of this article developed a biomimetic codelivery system using albumin nanoparticles (termed S/P NP) to co-encapsulate PTX and shikonin (SHK), a natural inhibitor of PKM2. By inhibiting PKM2, SHK suppressed β-Catenin signaling, thereby reversing CSC stemness and preventing VM formation. The S/P NP system exhibited tumor-targeting delivery effect and significantly inhibited TNBC growth and lung metastasis. Mechanistically, the treatment reversed epithelial–mesenchymal transition (EMT) and stem-like properties of TNBC cells, suppressed VM formation, and remodeled the TIME. It reduced immunosuppressive cells (M2 macrophages, MDSCs) while promoting anti-tumor immunity (M1 macrophages, dendritic cells, cytotoxic T cells, and memory T cells).

This dual-action strategy holds promise for improving TNBC therapy by targeting CSCs, VM, and the immune microenvironment, and for overcoming PTX resistance and reducing metastasis.

Keywords: Shikonin, Paclitaxel, Triple-negative breast cancer, Pyruvate kinase M2 (PKM2), Cancer stem-like cells, Vasculogenic mimicry, Tumor microenvironment, Albumin

Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383525002382-ga1_lrg.jpg

A combination therapeutic strategy using the albumin co-loading shikonin (SHK) and paclitaxel (PTX) was developed for TNBC treatment, which can inhibit PKM2 and β-Catenin, leading to suppression stem-property and vasculogenic mimicry.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.